【摘要】 目的探讨吡格列酮治疗2型糖尿病合并冠心病患者对其动脉粥样硬化相关危险因素及预后的影响。方法选取2010年8月至2012年1月在本院进行治疗的2型糖尿病合并冠心病患者202例,随机分为治疗组和对照组,两组均给予常规治疗;在此基础上,治疗组(101例)加用吡格列酮(15mg/次,1次/天)治疗,期间定期随访,1年后比较2组血液动脉粥样硬化相关危险因素及心血管不良事件发生率。结果治疗组血清PAI-1(纤溶酶原激活物抑制物-1)水平为(4.15±0.47)ng/ml,P-选择素水平为(12.38±3.56)ng/ml,对照组血清PAI-1水平为(7.46±1.73)ng/ml,P-选择素水平为(15.84±6.32)ng/ml,两组比较差异显著(P<0.05);治疗组空腹血糖、餐后血糖、空腹胰岛素、糖化血红蛋白水平和胰岛素抵抗指数及急性冠脉综合征、不稳定性心绞痛和靶血管重建发生率显著低于对照组,(P<0.05)。结论吡格列酮用于治疗2型糖尿病合并冠心病,能降低其动脉粥样硬化相关危险因素从而改善预后。更多还原

【Abstract】 Objective To investigate the effects of atherosclerosis-related factors and prognosis of pioglitazone in the treatment of type 2 diabetes patients with coronary heart disease.Methods From August 2010 to January 2012,there were 202 patients in our hospital been treated for treatment of type 2 diabetes with coronary heart disease,and they were randomly divided into the treatment group(101cases) and the control group.The two groups were both given conventional treatment,and on this basis,the treatment group plus pioglitazone treatment(15 mg/d,qd).After 1 year regular follow-up period,compared the atherosclerosis risk factors and adverse cardiovascular events.Results In treatment group,the serum PAI-1 level was 4.15±0.47 ng/ml,P-selectin level was 12.38±3.56 ng/ml,in control group,the serum PAI-1 level was 7.46±1.73 ng/ml,P-selectin level was 15.84±6.32 ng/ml,significant difference(P < 0.05);fasting blood glucose,postprandial glucose,fasting insulin,glycated hemoglobin levels and insulin resistance index and acute coronary syndrome,unstable angina pectoris Jinger target vessel revascularization in the treatment group were significantly lower than those in the control group(P < 0.05).Conclusion Pioglitazone for the treatment of type 2 diabetes patients with coronary heart disease,which could reduce atherosclerosis risk factors and thus improve prognosis.更多还原